Table I.
miR status in cancer-associated fibroblasts of various cancer types.
| Cancer type | miR profile | Status | Target genes |
|---|---|---|---|
| Breast | miR-221-5p, miRNA-221-3p, miR-31-3p and miR-21 | ↑ | TGF-β, IL-6, HGF, ETS-2 and Ki-67 |
| miR-26b, miR-101, miR-141, miR-200b, miR-200c, miR-205, miR-342-3p, let-7g and miR-320 | ↓ | ||
| Bladder | miR-16 and miR-320 | ↑ | TNF-α, FGF-inducible4 and pro-angiogenic miR |
| miR-143 and miR-145 | ↓ | ||
| Ovarian | miR-155 | ↑ | CCL5 or other chemokines secreted by CAFs |
| miR-31 and miR-214 | ↓ | ||
| Gastric | miR-143 | ↑ | TGF-β/Smad |
| Endometrial | miR-148 | ↓ | Wnt-1 and Wnt-10 |
| Prostate | miR-15 and miR-16 | ↓ | Bcl-2, Wnt, Bmi-1, Ccne1, Ccnd1, VEGF and IL-6 |
| SCC | miR-21 | ↑ | TPM1, TPM3 and TGF-β |
| Colorectal | miR-21 | ↑ | PDCD4, SPRY1, SPRY2, NFI-B, RECK and PTEN |
| NSCLC | miR-186 | ↑ | Glut1, CDK216, CCND1 and CkIIa mRAN |
SCC, squamous cell carcinoma; NSCLC, non small cell lung cancer; miR, microRNA; ↑, upregulated; ↓, downregulated.